SynthesisSurgical endoscopy2025
Safety and feasibility of argon plasma coagulation for gastric low-grade dysplasia: a systematic review and meta-analysis.
Synthesis in Surgical endoscopy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Argon plasma coagulation, endoscopic mucosal resection, and endoscopic submucosal dissection for gastric low-grade dysplasia: a multicenter inverse probability-weighted cohort study.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026Observational
- A New Endoscopic Device to Facilitate APC Treatment: First Multicenter Clinical Experience.Endoscopy international open · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsGastric low-grade dysplasia (LGD), as precancerous lesions, carry a risk of progressing to carcinoma, particularly in elderly or high-risk patients. Standard treatments like endoscopic submucosal dissection (ESD) can be technically challenging and risky. Argon plasma coagulation (APC) has emerged as a less invasive alternative with shorter procedural times but potentially higher local recurrence rates. This review evaluates the safety and feasibility of APC for managing gastric LGD.
methodsA systematic review following PRISMA guidelines included studies from MEDLINE, Embase, CINAHL, and Cochrane Library on APC for gastric LGD. Data on recurrence, bleeding, perforation, and procedural time were analyzed through meta-analysis.
resultsFrom 3409 studies, 10 met inclusion criteria. APC showed a recurrence rate of 4.5% (54/1208), with a pooled OR of 6.96 (95% CI 1.13-42.86, P = 0.95, I
conclusionAPC is a safe and efficient option for treating gastric LGD in selected patients, with shorter procedural times and low rates of complications. However, its higher recurrence risk for larger lesions highlights the need for careful patient selection and further research.
Indexed as
Identifiers
40634719What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.